IC Clinical Trials
Here are the 2 most popular medical studies for ic
Ondansetron +1 More for Alcoholism
The purpose of this study is to learn whether ondansetron and topiramate either alone or in combination is safe and effective in the treatment of alcohol dependence. This 13 week out-patient clinical trial is randomized, double-blind, and placebo-controlled. There are post-study follow up visits 1, 2 and 3 months after the end of the study. Participants will receive ondansetron and topiramate either alone or in combination or a placebo coupled with psychotherapy.
Selective Serotonin Reuptake Inhibitor
Fluoxetine for Anxiety and Depression
This trial uses fMRI to study brain regions engaged in processing motivationally salient stimuli in children, adolescents, and adults with mood and anxiety disorders, in order to better understand how these disorders develop and how they can be treated.
Frequently Asked Questions
Introduction to ic
What are the top hospitals conducting ic research?
When it comes to cutting-edge clinical trials in the field of interstitial cystitis (IC), hospitals across the United States are making strides towards understanding and treating this condition. In Houston, MD Anderson Cancer Center leads the way with five ongoing IC trials, demonstrating their commitment to finding innovative solutions for patients. Similarly, Stanford University in Stanford is actively involved in four IC trials, having already recorded one trial back in 2009. This renowned university is dedicated to pushing boundaries and expanding knowledge on IC. Meanwhile, Washington University School of Medicine in Saint Louis has also joined the effort with four active IC trials, showcasing their dedication to exploring new treatment options for affected individuals.
Moving eastward to New york City, Columbia University Medical Center is embarking on three active IC trials as they work tirelessly toward unraveling the complexities of this condition. Simultaneously, Memorial Sloan Kettering Cancer Center stands alongside them with three ongoing clinical investigations focused on IC.
Interstitial cystitis presents unique challenges and impacts countless lives worldwide. However, these top hospitals are determined to break new ground and improve outcomes for those living with this debilitating condition through rigorous research endeavors and collaborative efforts. Together they represent a beacon of hope for individuals suffering from interstitial cystitis while striving relentlessly to uncover better treatments and ultimately provide relief for patients everywhere
Which are the best cities for ic clinical trials?
When it comes to clinical trials for IC (interstitial cystitis), several cities stand out as top destinations for research and innovation. New york City leads the way with 22 active trials, focusing on treatments like Soticlestat, Selpercatinib, and Adapted IPS. Los Angeles follows closely behind with 19 ongoing studies investigating Encorafenib, Selpercatinib, and Cytology Specimen Collection Procedure. Philadelphia and Houston tie at 14 active trials each, exploring various interventions such as Tirzepatide Dose 2 and Tetrodotoxin for injection respectively. Lastly, Atlanta contributes to the field with 13 active trials investigating SEP-363856 and Half Dose Pantoprazole plus matching placebo among others. These cities provide individuals living with IC access to cutting-edge clinical trials that pave the way for improved management of this condition.
Which are the top treatments for ic being explored in clinical trials?
In the realm of clinical trials, there are several top treatments currently being explored for ic. These include:
- Daratumumab: with 6 active trials and a total of 134 breast cancer trials since its introduction in 2012.
- Belantamab mafodotin: showing promise in 4 ongoing trials and having participated in 26 all-time breast cancer studies since its arrival in 2018.
- Lenalidomide: involved in three current research projects focused on breast cancer and an impressive tally of 280 all-time clinical trials since debuting back in 2003.
What are the most recent clinical trials for ic?
Exciting advancements are taking place in the field of interstitial cystitis (IC) research, with several recent clinical trials offering new possibilities for patients. One notable trial is investigating the effectiveness of deucravacitinib, a potential treatment for IC that has entered phase 4. Additionally, rifaximin 550 MG oral tablet (XIFAXAN), currently in phases 2 and 3, shows promise as a therapeutic option. Another study explores the combination of BIIB091 and DRF standard dose to address IC symptoms in phase 2. Furthermore, dose exploration is being conducted as part A of a phase 1 trial for IC treatment options. Finally, GEM-ABR (Gemcitabine - Abraxane) therapy coupled with TheraBionic device usage is being examined in phase 2 trials. These ongoing investigations hold great potential to improve outcomes and quality of life for individuals living with interstitial cystitis.
What ic clinical trials were recently completed?
A recent clinical trial investigating the efficacy of low-dose naltrexone in treating ic has been completed. Sponsored by NorthShore University HealthSystem, this trial concluded in September 2021. The results of this study are anticipated to shed light on potential therapeutic options and help improve the management of ic for patients.